Screening for Fabry Disease in Renal Transplantation (DEFYT)
Status
Conditions
Treatments
Study type
Funder types
Identifiers
Details and patient eligibility
About
Single centre, prospective pilot study examining the relevance to screen for Fabry disease in a cohort of patients who have undergone renal transplantation for nephropathy of indeterminate cause, vascular nephropathy, diabetic nephropathy or secondary focal segmental hyalinosis with no established cause.
Full description
Exploration whether Fabry disease cases can be identified among patients who are followed at the Montpellier University Hospital after renal transplantation, with indeterminate cause of renal failure or diabetic nephropathy (due to its high frequency) or secondary focal segmental hyalinosis (FSH).
At the population level, the identification of cases at the Montpellier centre could then justify to expand this screening to other French centres. The goal is to contribute to adapt current guidelines of renal failure assessment, by systematically including Fabry among the diagnostic tests. Whether all patients with renal failure are concerned, or only those with indeterminate cause, is an important question this study will address.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Nephropathy of indeterminate cause, or secondary FSH or diabetic nephropathy
- Patients with kidney transplanted
- Patients still followed at the Montpellier University Hospital
- Obtaining written informed consent
- Age > 18 years old, no upper age limit
Exclusion criteria
- N/A
Trial contacts and locations
Loading...
Central trial contact
Moglie Le Quintrec, Pr
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal